Total IGF-I level is a suitable marker of IGF-I bioactivity in emaciated patients with AN irrespective of the clinical subtype and acute nutritional state.
Objective
Comorbid mental disorders in anorexia nervosa during long‐term course require detailed studies.
Method
This matched cohort study was based on nationwide Danish register data of all patients born 1961–2008 with a first‐time ICD‐10 diagnosis of anorexia nervosa (AN) between 1994 and 2018 at age 8–32 and matched controls taken from all individuals without an eating disorder (ED). For nine categories of non‐eating mental disorders, time from date of first AN‐diagnosis (inclusion date) to time of first diagnosis, accounting for censoring, was studied by use of time‐stratified Cox models.
Results
A total of 9,985 patients with AN (93.5% females) and 49,351 matched controls were followed for a median (IQR) of 9.0 (4.4–15.7) years. For patients, there was about 25% and 55% risk of receiving any non‐ED disorder during the first 2 years and two decades after inclusion, respectively. A hazard ratio (HR) of seven for any non‐ED was found for the first 12 months after inclusion, a ratio that reduced to two at five or more years after inclusion. During the first years, large HRs ranging in 6–9 were found for affective, autism spectrum, personality, and obsessive–compulsive disorders with the latter displaying the highest continuous increased risk. The HR at 12 months after inclusion was highest for any non‐ED disorder and affective disorders in patients aged 8–13 at diagnosis.
Discussion
Comorbid mental disorders in AN are most frequently diagnosed in the first years after diagnosis of AN and on longer terms imply a double immediate risk.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.